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Abstract
Impairments in mitochondria and transcription are important factors in the pathogenesis of Huntington disease (HD), a
neurodegenerative disease caused by a polyglutamine expansion in the huntingtin protein. This study investigated the
effect of different metabolic states and peroxisome proliferator-activated receptor c (PPARc) activation on sensitivity to
cellular stressors such as H2O2 or thapsigargin in HD. Striatal precursor cells expressing wild type (STHdh
Q7) or mutant
huntingtin (STHdh
Q111) were prepared in different metabolic conditions (glucose vs. pyruvate). Due to the fact that
STHdh
Q111 cells exhibit mitochondrial deficits, we expected that in the pyruvate condition, where ATP is generated primarily
by the mitochondria, there would be greater differences in cell death between the two cell types compared to the glucose
condition. Intriguingly, it was the glucose condition that gave rise to greater differences in cell death. In the glucose
condition, thapsigargin treatment resulted in a more rapid loss of mitochondrial membrane potential (DYm), a greater
activation of caspases (3, 8, and 9), and a significant increase in superoxide/reactive oxygen species (ROS) in STHdh
Q111
compared to STHdh
Q7, while both cell types showed similar kinetics of DYm-loss and similar levels of superoxide/ROS in the
pyruvate condition. This suggests that bioenergetic deficiencies are not the primary contributor to the enhanced sensitivity
of STHdh
Q111 cells to stressors compared to the STHdh
Q7 cells. PPARc activation significantly attenuated thapsigargin-
induced cell death, concomitant with an inhibition of caspase activation, a delay in DYm loss, and a reduction of
superoxide/ROS generation in STHdh
Q111 cells. Expression of mutant huntingtin in primary neurons induced superoxide/
ROS, an effect that was significantly reduced by constitutively active PPARc. These results provide significant insight into the
bioenergetic disturbances in HD with PPARc being a potential therapeutic target for HD.
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Introduction
Huntington disease (HD) is an inherited neurodegenerative
disease caused by an abnormal expansion of polyglutamine in the
huntingtin (Htt) protein. Neuronal degeneration in HD patients
begins in the striatum, especially GABAergic medium size spiny
neurons, followed by involvement of the cerebral cortex as the
disease progresses [1]. Despite the discovery of the unique
causative genetic mutation of Htt almost two decades ago [2]
there is still no satisfactorily effective treatment, and the underlying
pathogenic mechanisms of HD are still elusive. Bioenergetic
deficits manifested as weight loss, muscle wasting, reduced glucose
uptake in cortex and striatum, and increased incidence of diabetes
have been implicated in the pathogenic progression of HD [3,4,5].
Importantly, an increasing number of studies have shown that
mutant Htt (mHtt) results in mitochondrial impairment such as
deficits in the electron transport chain, Ca
2+ handling defects, and
increased sensitivity of mitochondria to permeability transition
pore (mPTP) opening [4,5,6,7]. Furthermore, numerous studies
have demonstrated that oxidative stress plays a pivotal role in the
pathogenesis of HD [8,9,10].
Transcriptional dysregulation has been considered a crucial
pathogenic mechanism in HD [5,11]. Many studies have reported
that the nuclear localization of mHtt leads to dysregulation of
transcriptional factors/cofactors including peroxisome prolifera-
tor-activated receptor c (PPARc) coactivator-1a (PGC-1a) [12].
PGC-1a is a master regulator of mitochondrial functions as it
regulates the expression of genes involved in mitochondrial
bioenergetics and respiration, detoxification of ROS, and
thermogenesis. PGC-1a is repressed in models of HD and PGC-
1a expression significantly protects striatal neurons from mHtt-
induced toxicity [12]. PGC-1a acts as a transcriptional coactivator
via interaction with a variety of transcription factors including
PPARc of the PPAR family. PPARc is an important regulator in
adipogenesis, fatty acid oxidation, and mitochondrial function.
PPARc hetero-dimerizes with retinoid X receptor (RXR) [13].
Upon ligand binding, PPARc transactivates the target genes with
the support of coactivators including PGC-1a. Thiazolidinediones
(e.g., rosiglitazone (RSG), pioglitazone, troglitazone) are exoge-
nous PPARc agonists which have been clinically used to treat type
2 diabetes. PPARc activation is beneficial in the R6/2 mouse
model of HD [14] as well as other models of neurological diseases
PLoS ONE | www.plosone.org 1 January 2012 | Volume 7 | Issue 1 | e30406[15,16,17,18,19]. Our previous study showed that PPARc activity
was severely compromised in STHdh
Q111 cells (striatal cells
expressing mHtt) [6]. Further, thapsigargin (TG) induced a loss of
mitochondrial membrane potential (DYm) in STHdh
Q111 but not
STHdh
Q7 cells (striatal cells expressing Htt) and RSG treatment
attenuated TG-induced DYm loss in STHdh
Q111 cells [6]. These
Figure 1. Mutant huntingtin expression sensitizes striatal cells to stressors in the glucose condition. A,H 2O2 treatment in the glucose
condition results in significantly greater cell death in STHdh
Q111 than STHdh
Q7 cells, while both cell types show similar cell death responses to H2O2 in
pyruvate condition. n=4.B, RSG treatment does not protect striatal cells from H2O2 toxicity. n=3–4. C, TG treatment in the glucose condition results
in much greater cell death in STHdh
Q111 than STHdh
Q7 cells, while both cell types show similar cell death responses to TG in the pyruvate condition.
n=4–6. D, RSG significantly attenuates TG-induced cell death in the glucose and pyruvate conditions. n=3–4. RP, rolipram. Data shown are mean 6
SE. * P,0.05, ** P,0.01.
doi:10.1371/journal.pone.0030406.g001
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with mitochondria defects and that activating the impaired
transcriptional pathways is likely to have beneficial effects in HD.
Given that bioenergetic disturbance has emerged as a key
component in the pathogenesis of HD, in the present study we
hypothesized that different metabolic conditions (glucose vs.
pyruvate) would differentially impact cell death induced by
stressors such as H2O2 or TG in HD and wild type models. In
addition, although we previously showed that TG-induced DYm
loss in STHdh
Q111 cells was attenuated by PPARc activation,
whether PPARc activation protects striatal cells from stress-
induced cell death remained untested. Therefore, we investigated
further whether the pathological changes induced by stresses can
be rescued by PPARc activation. We expected that STHdh
Q111
cells would show greater cell death compared to STHdh
Q7 cells,
and that the pyruvate condition would exacerbate the differences
in cell death between the two cell types compared to what was
observed in the glucose condition because there are numerous
studies showing mitochondrial impairment in HD models,
including deficits in ATP production [20,21]. Unexpectedly but
intriguingly, the glucose condition resulted in much greater
differences in stress-induced cell death between the two cell types.
These findings suggest that the bioenergetic status of the
STHdh
Q111 cells is not a major contributor to the enhanced
sensitivity to cell death stressors, and that other variables likely
play a more important role. Further, PPARc activation protected
STHdh
Q111 cells against stresses and significantly reduced
superoxide/ROS generation in STHdh
Q111 cells and primary
cortical neurons expressing mHtt. These results provide important
insight into the pathogenesis of HD involving transcriptional
dysregulation, oxidative stress, and metabolic impairment, and
suggest that PPARc may be a potential therapeutic target for HD.
Results
Mutant Huntingtin Sensitizes Striatal Cells to Stressors in
the Glucose Condition
To investigate if metabolic conditions differentially affect the
susceptibility of striatal cells expressing Htt or mHtt to different
stressors, striatal cells were maintained in media containing
glucose which supports both glycolysis and oxidative phosphory-
lation (Oxphos) or pyruvate which predominantly supports
Oxphos [22,23]. Striatal cells were treated with different
concentrations of H2O2 or TG for 12 h and cell death was
assessed by measuring LDH release. Unexpectedly, in the glucose
condition STHdh
Q111 cells showed much greater cell death in
response to H2O2 or TG compared to STHdh
Q7 cells, while in the
pyruvate condition both cell types showed a similar cell death
response (Fig. 1, A and C). It should be noted that LDH release
may be underestimated in the pyruvate condition because
pyruvate acts as a competitive inhibitor in the LDH assay [24].
Hence, it is not appropriate to compare the extent of LDH release
between the glucose and pyruvate conditions. To further confirm
the results from the LDH assay, cell viability was also measured
using the resazurin assay (Fig. 2) [25]. As with the LDH assay
(Fig. 1), greater differences in response to stressors between the two
cell types were observed in the glucose condition as compared to
the pyruvate condition when viability was measured with the
resazurin assay (Fig. 2). Together these results demonstrate that
mHtt sensitizes striatal cells to stressors in the glucose condition,
while striatal cells expressing either Htt or mHtt show similar
susceptibility to stressors in the pyruvate condition.
Since cells in the glucose condition utilize glycolysis as well as
Oxphos, cells were treated with Oxphos inhibitors in the glucose
medium to further understand how the different metabolic
conditions affect the susceptibility to cellular stress (Fig. S1).
STHdh
Q111 cells in the presence of either oligomycin, a complex
V inhibitor, or rotenone, a complex I inhibitor, showed greater cell
death in response to H2O2 or TG compared to STHdh
Q7 cells,
suggesting that glycolysis may be a critical factor in rendering
striatal cells expressing mHtt more sensitive to stressors. Since the
concentration of glucose in media was high (25 mM), we also
measured cell death in low (5 mM) glucose to determine if the
greater difference in cell death between the two cell types in the
glucose condition compared to the pyruvate condition was due to
the effect of high glucose or the metabolic state. In 5 mM glucose,
STHdh
Q111 cells exhibited a similar cell death profile in response
to H2O2 or TG as observed in 25 mM glucose (Fig. S2), indicating
that it is the metabolic condition that contributes to the differential
cell death. Next, we examined whether the PPARc agonist, RSG
attenuated cell death in response to H2O2 or TG. Striatal cells
were pretreated with RSG for 24 h prior to treatment with H2O2
or TG. RSG treatment significantly reduced cell death in response
to TG but not H2O2 in both glucose and pyruvate conditions
(Fig. 1, B and D). We also tested whether treatment with rolipram
(RP), a phosphodiesterase IV (PDE4) inhibitor, attenuated TG-
induced cell death, since intracellular cAMP levels are decreased
in HD models and RP treatment has beneficial effects [26,27].
However, RP did not attenuate TG-induced cell death (Fig. 1D).
In addition, an endogenous PPARc agonist 15-d-PGJ2 also
protected STHdh
Q111 cells from TG-induced death (data not
shown).
Repressed PPARc Activity Is Independent of the Protein
Level
We previously showed that PPARc signaling is impaired in
STHdh
Q111 cells [6]. To confirm that disturbance of PPARc
signaling was due to the presence of mHtt we measured PPARc
activity in additional striatal cell lines. Two new striatal cell lines
expressing mHtt (1A and 6L) exhibited a substantial reduction in
the basal activity of PPARc compared to two new striatal cell lines
expressing Htt (B3 and E4) (Fig. 3A). Furthermore, CRE basal
activity and PGC-1a promoter activity were also significantly
compromised in 1A and 6L STHdh
Q111 cells, which is in
agreement with previous reports (Fig. 3, B and C) [6,12].
However, we found that PPARc protein levels were variable in
B3 and E4 while the original STHdh
Q111 cells exhibited lower
levels of PPARc than the original STHdh
Q7 cells (Fig. 3D). This
result indicates that the repressed activity of PPARc is indepen-
dent of its expression level.
Protective Effect of Rosiglitazone Is Due to the Specific
Activation of PPARc
To determine if the protective effects of RSG on TG-induced
cell death were specifically due to PPARc activation, we co-
administered GW9662, a PPARc antagonist, with RSG for 24 h
prior to TG treatment. GW9662 completely abolished the
protective effects of RSG on TG-induced cell death, suggesting
that the protective effect of RSG stems from PPARc activation
(Fig. 4A). To test whether the reduced activity of PPARc in striatal
cells is sufficient to sensitize striatal cells to stressors in the glucose
condition, shRNA for PPARc was stably expressed in STHdh
Q7
cells (Fig. S3). The stable expression of shRNA- PPARc
significantly reduced the activity of PPARc in STHdh
Q7 cells
(Fig. S3A). However, cell death induced by treatment with H2O2
or TG was not significantly increased by the stable expression of
shRNA- PPARc in STHdh
Q7 cells (Fig. S3B). This result suggests
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sensitization of STHdh
Q111 cells to stressors in the glucose
condition.
We next examined how RSG treatment affected the expression
of specific genes in STHdh
Q7 and STHdh
Q111 cells. Striatal cells
were incubated with or without 24 h of RSG treatment in the
glucose condition prior to collection. Quantitative RT-PCR was
performed as described in materials and methods (Fig. 4B).
STHdh
Q111 cells show a significantly reduced expression of genes
related to mitochondrial function [PPARc, cytochrome C (CytC),
uncoupling proteins (UCP4, UCP5)], calcium regulation [sar-
co(endo)plasmic reticulum Ca
2+-ATPase 2 (SERCA2)], and ROS
response [superoxide dismutase 1 (SOD1)]. SOD2 appears to be
decreased in STHdh
Q111 cells. Retinoid X receptor a (RXRa), an
obligatory signaling partner of PPARc, appears to be increased in
STHdh
Q111 cells, suggesting that the reduced activity of PPARc is
not attributable to RXRa expression. RSG significantly upregu-
lated CytC, UCP4, UCP5, SOD1, and SERCA2 in STHdh
Q111
but not STHdh
Q7 cells. PPARc, RXRa, and SIRT1 showed no
change after RSG treatment in both cell types. UCP2 was
significantly increased and appeared to be further induced by RSG
treatment in STHdh
Q111 cells. PGC-1a trended higher in both cell
types after RSG treatment but the increase was not statistically
significant. PGC-1a gene regulation in STHdh
Q111 cells was
further investigated using PGC-1a promoter luciferase reporter
assay (Fig. 4C). RSG induced a slight but significant increase of
PGC-1a promoter activity and mutation of the PPAR-response
element (PPRE), but not the cAMP response element (CRE) site,
in the PGC-1a promoter completely abolished RSG-induced
activation. These results suggest that PGC-1a expression is likely
upregulated by RSG treatment in STHdh
Q111 cells. Immunoblot
of CytC showed a significantly reduced level in STHdh
Q111 cells
compared to STHdh
Q7 cells. RSG increased CytC expression in
STHdh
Q111 but not STHdh
Q7 cells, confirming the quantitative
RT-PCR data (Fig. 4, B and D).
Metabolic Conditions Differentially Impact Mitochondrial
Membrane Potential Loss (DYm) in Response to
Thapsigargin
DYm is tightly linked with mitochondrial functions such as Ca
2+
buffering, ATP synthesis, and cell death processes [28]. In order to
understand how different metabolic conditions result in different
patterns of TG-induced cell death, we monitored DYm using JC-1
dye [29,30]. Treatment with FCCP, a mitochondrial uncoupler,
markedly reduced the JC-1 ratio, validating the response of JC-1
dye to DYm (data not shown). TG treatment increased the DYm
at early time points in both cell types in both metabolic conditions.
DYm in STHdh
Q111 cells began to drop 2 h after TG treatment in
the glucose condition, while STHdh
Q7 cells maintained DYm
above the base line until 6 h. TG treatment in the pyruvate
condition resulted in similar kinetic responses in both cell types
with the DYm dropping below the base line after 4 h (Fig. 5A).
These results suggest that the distinct kinetic responses in TG-
induced DYm-loss in the different metabolic conditions may be a
contributing factor to the different cell death profiles. We next
tested whether RSG affects TG-induced DYm loss. DYm was
measured 5 h after adding TG (Fig. 5B). Treatment of STHdh
Q7,
but not STHdh
Q111 cells, with RSG dramatically increased the
basal level of DYm in both glucose and pyruvate conditions. RSG
treatment slightly but significantly delayed TG-induced DYm-loss
of STHdh
Q111 cells, an effect that was completely abrogated by
GW9662 treatment, indicating the specific activation of PPARc by
RSG treatment.
Figure 2. Mutant huntingtin expression exacerbates striatal cell viability loss in response to stressors in the glucose condition.
Striatal cells were maintained in the different metabolic conditions. Cell viability was measured 8 h after treatment H2O2 (A)o rT G( B) using the
resazurin assay. Treatment with H2O2 or TG in the glucose condition significantly reduces the viability of STHdh
Q111 cells compared to STHdh
Q7 cells,
while both cell types show similar viability responses to H2O2 or TG in the pyruvate condition. n=3. Data shown are mean 6 SE.
doi:10.1371/journal.pone.0030406.g002
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by Thapsigargin
Next, since caspase activation plays a pivotal role in cell death
processes, we tested whether caspase activation is involved in TG-
induced cell death and if RSG attenuates caspase activation. TG
treatment resulted in the formation of cleaved caspase 3, an active
form of caspase 3, after 3 h in both cell types in the glucose
condition (Fig. 6A). RSG dramatically reduced the level of cleaved
caspase 3 in both cell types. Interestingly, the basal level of cleaved
caspase 3 in STHdh
Q111 cells is much higher compared to
STHdh
Q7 cells and substantially decreased by RSG treatment,
while the total level of caspase 3 is similar between two cell types.
The basal level of caspase 9 in STHdh
Q111 cells was higher than in
STHdh
Q7 cells (Fig. 6E). The total levels of caspase 3 and 9 were
not changed in response to TG or by RSG treatment. TG strongly
induced cleaved PARP (poly ADP-ribose polymerase), another
indicator of caspase 3 activation, and RSG reduced the level of
cleaved PARP in both cell types. Although these results indicate
that RSG ameliorates TG-induced cell death in part by
attenuating caspase activation, these results do not explain why
TG-induced cell death is significantly greater in STHdh
Q111 cells.
Because immunoblot based assays do not represent the real
activity of caspases, we next measured the activity of three
different caspases in response to TG (Fig. 6, B–D). TG significantly
increased the activities of caspase 3 and 9 in STHdh
Q111 cells,
while STHdh
Q7 cells only exhibited increased activity of caspase 3
and to a much lesser extent than STHdh
Q111 cells. In addition,
caspase 8 activity was measured since TG increases the activity of
caspase 8 [31,32] and caspase 8 is implicated in HD [33,34,35].
Caspase 8 activity in STHdh
Q111, but not STHdh
Q7 cells, was
significantly increased by TG treatment. RSG significantly
diminished TG-induced activation of these caspases in
STHdh
Q111 cells. These results suggest that the greater cell death
in STHdh
Q111 cells by TG treatment may be due to the greater
activation of caspases which is reduced by RSG. Furthermore,
STHdh
Q111 cells display higher basal activities of caspase 3, 8, and
9, which is in line with the immunoblot results. The higher basal
activities of caspases may also contribute to the greater sensitivity
of STHdh
Q111 cells to the stressors.
Stable Expression of Constitutively Active PPARc
Significantly Attenuates Cell Death Induced by H2O2 or
Thapsigargin
It has been shown that RSG may affect signaling pathways
independent of PPARc pathway [36]. Therefore, we tested
whether the protective effect of RSG mainly results from PPARc
activation. We established STHdh
Q111 cells stably expressing
constitutively active PPARc, V16- PPARc2 (Fig. 7A). Stable
expression of VP16- PPARc2 significantly increased PPARc
activity at the basal level (Fig. 7B). #41 cell line exhibited greater
PPARc activity than #12 cell line, although the expression levels
of VP16- PPARc2 were similar between two cell lines.
Importantly, both #12 and #41 cell lines exhibited the greater
activity of PPARc compared to STHdh
Q7 cells and showed
significantly reduced cell death in response to H2O2 or TG in a
PPARc activity dependent manner (Fig. 7, C and D). These results
Figure 3. Mutant huntingtin results in repressed transcriptional activities, and reduced PPARc activity is independent of the
protein level. B3 and E4 STHdh
Q7 cells and 1A and 6L STHdh
Q111 cells were transiently transfected with PPRE, CRE, or PGC-1a promoter luciferase
reporter plasmids. The basal activities of PPRE (A), CRE (B), and PGC-1a promoter (C) reporters were dramatically reduced in both 1A and 6L
STHdh
Q111 cells. n=3–4 Data shown are mean 6 SE. D, PPARc protein levels were variable in B3 and E4 STHdh
Q7 cells and 1A and 6L STHdh
Q111 cells,
while the original STHdh
Q111 cells exhibited lower levels of PPARc than the original STHdh
Q7 cells. Sixty micrograms of protein was run in each lane.
doi:10.1371/journal.pone.0030406.g003
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protective effect of RSG.
Metabolic Condition Differentiates Superoxide/ROS
Generation in Response to Thapsigargin
We previously showed that TG induced a greater generation of
ROS in STHdh
Q111 cells compared to STHdh
Q7 cells [6].
Superoxide can be generated in mitochondria and cytosol and
contribute to cell death/stress signaling pathways. Hence we
measured superoxide levels in different metabolic conditions using
dihydroethidium (DHE), a commonly used dye for superoxide
detection, although it has been suggested that DHE may be
oxidized by other ROS [37]. Interestingly, different metabolic
conditions resulted in distinct patterns of superoxide/ROS
production (Fig. 8A). STHdh
Q111 cells show higher basal levels
Figure 4. The protective effect of RSG is due to the specific activation of PPARc. A, GW9662 (GW), a PPARc antagonist, abolishes the
protective effect of RSG on TG-induced cell death in the glucose and pyruvate conditions. n=4–6. 40 mM GW9662 was added in the presence or
absence of 20 mM RSG for 24 h prior to TG treatment. B, RSG increases the expression of genes involved in mitochondrial function (CytC, UCP2, UCP4,
UCP5), calcium regulation (SERCA2), and ROS response (SOD1, SOD2), but does not change the expression of PPARc and SIRT1. n=4–6. * P,0.05,




### P,0.001 vs. control of each cell type. Statistical significance was
determined by one-way ANOVA followed by Student-Newman-Keuls multiple comparisons test. C, PGC-1a promoter is slightly but significantly
activated by RSG in STHdh
Q111 cells. The mutation at PPRE but not CRE sites in PGC-1a promoter completely abolishes PGC-1a promoter activation
induced by RSG treatment. n=4–6. ** P,0.01, *** P,0.001 vs. control;
# P,0.05 vs. RSG. D, RSG increases the protein level of CytC in STHdh
Q111 but
not STHdh
Q7 cells. Data shown are mean 6 SE.
doi:10.1371/journal.pone.0030406.g004
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induced a substantial amount of superoxide/ROS in STHdh
Q111
but not STHdh
Q7 cells in the glucose condition, while in the
pyruvate condition TG significantly increased superoxide/ROS in
both cell types to a similar extent (Fig. 8, A and B). This result
suggests that the distinct cell death patterns between the two
different metabolic conditions in response to TG maybe in part
related to superoxide/ROS generation.
PPARc Activation Significantly Reduces Superoxide/ROS
Generation
PPARc plays an important role in regulating defense mecha-
nisms against oxidative stress [38]. Therefore, we investigated
whether PPARc activation ameliorates superoxide/ROS produc-
tion in HD cell models. We tested STHdh
Q111 cells stably
expressing VP16- PPARc2. The stable expression of VP16-
PPARc2 led to pronounced reductions in TG-induced superox-
ide/ROS generation in STHdh
Q111 cells in the glucose condition
(Fig. 9A). The quantitative data shows that TG-induced superox-
ide/ROS production is significantly attenuated in two stable cell
lines expressing VP16- PPARc2 (Fig. 9B), suggesting that the
protective effect of PPARc activation on TG-induced cell death
involves the regulation of oxidative responses including superox-
ide. We next investigated whether mHtt expression enhances
superoxide/ROS production in primary neurons. Rat primary
cortical neurons were transfected with vector, Htt (Htt568Q23), or
mHtt (Htt568Q145) on DIV 7 and superoxide/ROS generation
was measured 6 days later (Fig. 9, C–F). The expression of
Htt568Q23 and Htt568Q145 were verified by immunoblot of
HEK cells after transfection (Fig. 9D). Primary neurons expressing
Htt568Q145 exhibited a higher frequency of DHE positive cells
than those transfected with vector or Htt568Q23 (Fig. 9, C and E).
Next, we tested whether cotransfection of VP16- PPARc2 with
Htt568Q145 decreases the percentage of DHE positive neurons.
The frequency of DHE positive neurons was significantly reduced
by VP16- PPARc2 expression compared to cotransfection of an
empty vector with Htt568Q145 (Fig. 9F). For comparison, PGC-
1a was cotransfected with Htt568Q145, which also resulted in a
significant reduction in the percentage of DHE positive neurons
(Fig. 9F). These results suggest that mHtt increases oxidative stress,
presumably including superoxide, and that the activation of
PPARc/PGC-1a may be a promising target to protect neurons
from increased oxidative stress.
Discussion
Numerous studies have suggested that bioenergetic impairment
is an important contributing factor to HD pathogenesis [3,4,5].
These include the finding that the activity of the pyruvate
dehydrogenase complex (PDH), which links glycolysis and TCA
cycle/Oxphos, is significantly reduced in brain of HD patients
[39,40]. These studies led us to hypothesize that different
metabolic conditions may result in alterations in the susceptibility
of neuronal cells expressing mHtt to different stressors. Our initial
prediction was that in the pyruvate condition, where cellular
bioenergetics is predominantly dependent on mitochondrial
Oxphos, greater differences in cell death between STHdh
Q7 and
STHdh
Q111 cells would be observed. Unexpectedly, it was in the
glucose condition in which the greater differences between two cell
types were observed, with the extent of cell death induced by
H2O2 or TG being significantly greater in STHdh
Q111 cells. Our
initial hypothesis was that due to the mitochondrial deficits in the
Figure 5. Metabolic conditions differentiate DYm-loss in response to TG. A, In the glucose condition STHdh
Q111 cells undergo DYm-loss in
response to TG at a significantly faster rate than STHdh
Q7 cells. In the pyruvate condition, DYm of both cell types shows similar kinetics in response
to TG. Arrows indicate the point at which DYm begins to drop below the baseline. n=4.B, RSG slightly but significantly delays TG-induced DYm-loss
in glucose and pyruvate conditions. GW9662 abrogates the delayed DYm-loss by RSG treatment. n=5–9. Data shown are mean 6 SE. * P,0.05.
doi:10.1371/journal.pone.0030406.g005
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Q111 cells, specifically deficiencies in ATP production
[20,21], greater differences in stress-induced cell death would be
observed in the pyruvate condition. However in retrospect, it is not
surprising that the greater differences were observed in the glucose
condition. First, deficits in PDH have been reported in HD cases
[39,40], as well as in HD mouse models [41], which in
combination with other defects in mitochondria bioenergetics,
may make STHdh
Q111 cells more reliant on glycolysis for ATP
production, and thus more vulnerable to stress in the glucose
condition. Second, we assumed that a subtle energy deficiency
would be a pivotal contributor to cell death in response to H2O2 or
TG, however it is not unreasonable that other variables are more
important in determining cell death outcomes. Taken together,
our study provides new insight for understanding the interrela-
tionship between bioenergetic disturbances and the pathogenesis
in HD.
Increased caspase activation has been associated with HD
pathogenesis[33,34,35].Ourresultsdemonstratethattheprotective
mechanisms of PPARc activation against TG-induced cell death
involve a slight delay of DYm loss (Fig. 5) and inhibition of caspase
activation (Fig. 6). The basal activities of three caspases (3, 8, and 9)
were higher in STHdh
Q111 cells compared to STHdh
Q7 cells,
rendering mHtt-expressing striatal cells more vulnerable to various
stressors. A delay of DYm-loss could be a contributing factor to the
inhibitory effect of RSG on caspase activation. Since in the glucose
condition STHdh
Q111 cells exhibited much faster kinetics of TG-
induced DYm-loss than STHdh
Q7 cells, we also examined major
components of mPTP such as cyclophilin D (CypD) and voltage-
Figure 6. RSG reduces TG-induced caspase activation. A, TG induces the cleaved forms of caspase 3 and PARP in both cell types, responses
that were reduced by RSG. B, TG increases caspase 3 activity of STHdh
Q111 cells to a significantly greater extent compared to STHdh
Q7 cells, a
response that was significantly attenuated by RSG. Basal activity of caspase 3 in STHdh
Q111 cells was significantly higher compared to STHdh
Q7 cells.
n=5.C, TG increases caspase 8 activity in STHdh
Q111 but not STHdh
Q7 cells, a response that was significantly attenuated by RSG. Basal activity of
caspase 8 of STHdh
Q111 cells is significantly higher compared to STHdh
Q7 cells. n=5.D, TG increases caspase 9 activity in STHdh
Q111 but not STHdh
Q7
cells, a response that was significantly attenuated by RSG. Basal activity (D) and basal level (E) of caspase 9 in STHdh
Q111 cells are significantly higher
compared to STHdh
Q7 cells. n=4–5. Data shown are mean 6 SE. ** P,0.01, *** P,0.001 vs. control of each cell type;
## P,0.01,
### P,0.001 vs. TG
of each cell type;
+ P,0.05,
++ P,0.01 vs. control of STHdh
Q7. Statistical significance was determined by one-way ANOVA followed by Student-
Newman-Keuls multiple comparisons test (B, C, and D) or by Student’s t test (E).
doi:10.1371/journal.pone.0030406.g006
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expression of CypD supposedly increases the probability of mPTP
opening [42,43,44]. However, the basal expression of CypD was
lower at both the mRNA and protein level in STHdh
Q111 cells than
STHdh
Q7 cells, while the expression of VDAC appeared to be
equivalent in the two cell types. In addition, RSG treatment did not
alter the expression of CypD or VDAC (Fig. S4C). These results
suggest that the protective effect of RSG and the higher
susceptibility of STHdh
Q111 cells to TG may not be related to
mPTP. Similarly, a recent study using R6/2 mice crossed with
CypD knockoutmicedemonstratedthatthedeletionofCypDinthe
R6/2 mice resulted in enhanced mitochondrial Ca
2+ buffering but
did not show any improvement in the pathogenic symptoms or a
delay in disease progression [45]. Further, RSG has been reported
to protect cells against stresses by upregulation of PPARc and Bcl-2,
an anti-apoptotic protein that has been shown to be implicated with
HD [14,46]. To test whether the protective effect of RSG could be
due to an increase of Bcl-2 and/or PPARc, we monitored the
expression of Bcl-2 and PPARc in both cell types in the presence or
absence of RSG. STHdh
Q111 cells show significantly lower levels of
Bcl-2 and PPARc in the basal condition (Fig. S4, A and C). RSG
treatment did not affect the expression of Bcl-2 or PPARc (Fig.
S4C), indicating that the protective effect of RSG is not due to the
upregulation of Bcl-2 or PPARc.
TG-induced cell death can be mediated by endoplasmic
reticulum (ER) stress and unfolded protein response (UPR)
[47,48]. UPR induces the expression of the molecular chaperone
BiP/GRP78 and activates the ER-resident caspase-12 through
processing by calpain and caspase. TG did not induce the
expression of BiP/GRP78 or increase cleaved form of caspase 12
in two cell types. RSG did not alter BiP/GRP78 expression or
caspase 12 activation in the presence or absence of TG (Fig. S5).
This result suggests that the UPR is probably not a major
contributor to TG-induced cell death in these experimental
conditions, and the protective effect of RSG does not result from
modulation of UPR. However, interestingly, the pro and active
forms of caspase 12 are much higher in STHdh
Q111 cells
compared to STHdh
Q7 cells. Taken together with the higher
basal activity of caspase 3, 8, and 9, this result suggests that the
higher levels of the activity and/or expression of caspases may
render STHdh
Q111 cells more susceptible to cellular or exogenous
stresses.
mHtt has been proposed to impair mitochondrial function by
direct interaction [49,50] as well as indirectly by transcriptional
dysregulation including PGC-1a signaling [12]. PGC-1a and
PPARc play important roles in mitochondrial biogenesis and
detoxification of ROS. We previously demonstrated that PPARc
signaling was severely compromised in STHdh
Q111 cells [6].
Figure 7. Stable expression of constitutively active PPARc2, VP16- PPARc2, in STHdh
Q111 cells significantly attenuates cell death
induced by H2O2 and TG. A, VP16-PPARc2 is stably expressed in STHdh
Q111 cells. #12 and #41 clonal STHdh
Q111 cells were individually selected
and used for experiments. B, Stable expression of VP16- PPARc2 in STHdh
Q111 cells significantly increases PPARc activity in STHdh
Q111 cells. n=3.
Stable expression of VP16- PPARc2 in STHdh
Q111 cells significantly diminishes cell death in response to 0.6 mM H2O2 (C) and by 12 mMT G( D) in the
glucose condition. n=4–6. The efficiency to reduce cell death seems to be proportional to the PPARc activity. Data shown are mean 6 SE. * P,0.05,
** P,0.01, *** P,0.001 vs. vehicle control.
doi:10.1371/journal.pone.0030406.g007
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expression of genes under the control of PGC-1a/ PPARc such as
CytC and SOD1 were significantly downregulated and RSG
rescued reduced expression of those genes in STHdh
Q111 cells
(Fig. 4B). Despite the compromised signaling of PPARc, the basal
level of UCP2 was upregulated in STHdh
Q111 cells and further
induced by RSG treatment. Increased UCP2 at the basal level
could be due to genetic compensation by other PPAR family such
as PPARa and PPARb, since UCP2 can be upregulated by
PPARa and PPARb [51,52] or a response to increased superoxide
level in STHdh
Q111 cells as reported previously that superoxide
upregulates UCP2 level [53,54]. Furthermore, it has been
suggested that superoxide activates UCP2 [55,56]. Increased or
activated UCP2 may act as a protective mechanism in the
STHdh
Q111 cells [57]. The pyruvate condition resulted in a subtle
change in gene expression profiles compared to the glucose
condition (Fig. S6). The expression profiles of PGC-1a, PPARc,
SIRT1, UCP2, and UCP4 in the pyruvate condition were similar
to those shown in the glucose condition. However, in the pyruvate
condition the two cell lines exhibited similar levels of CytC, UCP5,
SOD1, SOD2, and SERCA2 which were shown to be decreased
in STHdh
Q111 cells in the glucose condition, suggesting that
different metabolic environments can alter gene regulation. Since
the levels of SOD1 and SOD2 were reduced in STHdh
Q111 cells
in the glucose condition but not in the pyruvate condition, we
investigated if superoxide/ROS generation in two cell types may
differ in different metabolic conditions. STHdh
Q111 cells produced
more superoxide/ROS at the basal level and in response to TG in
the glucose condition compared to STHdh
Q7 cells, while in the
pyruvate condition similar profiles of superoxide/ROS generation
were observed in both cell types (Fig. 8). The profiles of TG-
induced superoxide production in the two cell types in different
metabolic conditions are similar to those of TG-induced cell death,
suggesting that superoxide/ROS is likely to be a crucial mediator
of TG-induced cell death. In addition, a large body of evidence
provides evidence that PPARc activation reduces superoxide/
ROS generation in various models [38,58,59].
Oxidative stress has been proposed as one of key components in
the pathogenesis of HD [8,9,10]. Recent studies using proteomic
approaches identified proteins modified by oxidative stress in
human HD samples and R6/2 mice and the activities of oxidized
proteins were severely compromised [9,10]. Interestingly, many
identified proteins are involved in glycolysis or mitochondrial
metabolism, suggesting that oxidative stress could lead to
metabolic disturbances and neuronal dysfunction [9,10]. We
found that in the glucose condition STHdh
Q111 cells showed
reduced expression of genes involved in ROS response at least in
part due to the repressed signaling pathways of PPARc/PGC-1a
and produced higher levels of superoxide/ROS in basal condition
than STHdh
Q7 cells. We postulate that mHtt interferes with
transcriptional processes, leading to disruption in the expression of
genes involved in bioenergetics and ROS response, in turn
resulting in impaired metabolism and enhanced ROS. Increased
oxidative stress may have an impact on transcriptional processes.
For example, the promoter of SQSTM1/p62 exhibited oxidative
damage in samples from HD samples, resulting in decreased
expression of p62 [60].
In summary, we demonstrate for the first time that different
metabolic states result in surprisingly differential cellular sensitiv-
ities to stressors in the context of HD. We also directly
demonstrate that PPARc activation significantly attenuated
superoxide/ROS production and cell death in response to
stressors in striatal precursor cells and primary cortical neurons
expressing mHtt. This study provides new important insights into
a cycling feed forward mechanism in HD involving transcriptional
dysregulation, oxidative stress, and metabolic impairment and




All animal protocols have been approved by the UCAR at the
University of Rochester (UCAR#2007-023R).
Materials
Rosiglitazone (RSG), GW9662, rolipram (RP), thapsigargin
(TG), and caspase substrates were purchased from Alexis.
dihydroethidium (DHE) was purchased from Invitrogen. All other
chemicals were purchased from Sigma, if not otherwise indicated.
Plasmid Constructs
PPRE63-TK-Luc and human PGC-1a promoter-Luc were
obtained from Addgene [61,62]. The human PPARc and PGC-1a
constructs were purchased from OriGene. mutPPRE- PGC-1a
promoter-Luc and mutCRE- PGC-1a promoter-Luc were kindly
provided from Dr. Francesc Villarroya [63]. pCRE-Luc was
Figure 8. Metabolic conditions differentially affect superoxide/
ROS generation. A, In the glucose condition TG-induced superoxide/
ROS generation in STHdh
Q111 cells was greater compared to STHdh
Q7
cells, while in the pyruvate condition TG induced superoxide/ROS
generation to a similar extent in both cell types. B, The percentage of
DHE positive cells was calculated. Quantitative data shows the
differential effects of metabolic conditions on TG-induced superoxide/
ROS generation as shown in A. n=6. STHdh
Q111 cells display
significantly higher basal levels of superoxide/ROS compared to
STHdh
Q7 cells. Data shown are mean 6 SE. ** P,0.01, *** P,0.001.
doi:10.1371/journal.pone.0030406.g008
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from Dr. Mitchell Lazar. To make VP16- PPARc2-pHM6/PUR,
VP16- PPARc2 was amplified by PCR with primers containing
MfeI/NotI sites and subcloned into EcoRI/NotI sites of pHM6/
PUR. pHM6/PUR was made by inserting the blunt ended
puromycin resistance gene at the PsiI site of pHM6 (Roche). The
full length wild type human Htt DNA with 23 polyQ, pRc/CMV-
HDFLQ23, was a gift from Dr. Christopher Ross and the full
length mutant human Htt DNA with 145 polyQ was obtained
from CHDI. To make constructs of truncated huntingtin with 568
amino acids, Htt568Q23 and Htt568Q145, each fragment of the
huntingtin cDNA of Htt568Q23 and Htt568Q145 was generated
by PCR with primers including BamHI/EcoRI sites and the
respective full length huntingtin DNA was used as a template.
PCR products were digested with BamHI and EcoRI and then
subcloned into FIGB vector derived from FG12 vector [64]. FIGB
contains IRES-GFP so that transfected cells can be identified.
Cell Culture and Different Metabolic Media
The immortalized striatal precursor cell lines, STHdh
Q7 (the
original one, B3, E4) and STHdh
Q111 (the original one, 1A, 6L),
made from striatal primordia of E14 mouse embryos expressing
Htt with 7 polyQ or mHtt with 111 polyQ were kindly provided
by Dr. Marcy MacDonald [65]. Cells were cultured in DMEM
containing 25 mM glucose and 4 mM glutamine (Invitrogen)
supplemented with 4% fetal bovine serum (FBS, HyClone) and
4% bovine growth serum (BGS, HyClone), and 100 units/ml
penicillin and 100 mg/ml streptomycin (Invitrogen) in the
incubator at 33uC containing 5% CO2. For the two different
metabolic conditions, 24 h after plating, the medium was
Figure 9. PPARc activation significantly reduces superoxide/ROS generation. A and B, Stable expression of VP16- PPARc2 in STHdh
Q111
cells significantly reduces superoxide/ROS generation in response to TG. A, STHdh
Q111 cells and #12 and #41 STHdh
Q111 cells stably expressing VP16-
PPARc2 were treated with 12 mM TG for 1 h after adding 5 mM DHE for 10–15 min. Both cell lines stably expressing VP16- PPARc2 show significantly
lower level of superoxide/ROS generation than STHdh
Q111 cells. B, Quantitative results show significantly reduced DHE positive cells in response to
TG. n=5.*P,0.05 vs. TG of STHdh
Q111. C–F, Mutant huntingtin increases superoxide production, an effect that is significantly reduced by PPARc
activation in the primary rat cortical neuronal cells. C, Primary rat cortical neurons were transfected with vector, wild type Htt (Htt568Q23), or mHtt
(Htt568Q145) on DIV 7. Since all three plasmids contain IRES-GFP, GFP positive neurons were monitored for DHE staining on DIV 13. DHE nucleus
staining was observed more frequently in neurons transfected with Htt568Q145. Arrow indicates DHE stained nucleus. D, Vector, Htt568Q23, and
Htt568Q145 were transfected in HEK cells and the expression of wild type Htt and mHtt were verified by immunoblotting. Htt568Q145 migrates
much slower than Htt568Q23 due to the extensively long track of poly glutamine. E, DHE positive neurons were counted from all of transfected
neurons. Htt568Q145 transfection significantly increases the frequency of DHE positive neurons compared to vector or Htt568Q23 transfection. n=4.
* P,0.05 vs. vector. F, VP16- PPARc2 or PGC-1a cotransfection significantly reduces the frequency of DHE positive neurons transfected with
Htt568Q145. n=7.*P,0.05 vs. vector and Htt568Q145. Data shown are mean 6 SE.
doi:10.1371/journal.pone.0030406.g009
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[23]. Glucose medium consists of DMEM containing 25 mM
glucose and 4 mM glutamine supplemented with 10 mM Hepes
and 2% dialyzed FBS (HyClone). Pyruvate medium consists of
DMEM containing 4 mM glutamine without glucose (Invitrogen)
supplemented with 5 mM galactose, 10 mM Hepes, 4 mM
sodium pyruvate, and 2% dialyzed FBS. The dialyzed FBS is
necessary to rule out any exogenous metabolic contributions.
Generation of Stable Cell Lines
STHdh
Q111 cells were transfected with VP16- PPARc2-
pHM6/PUR using Lipofectamine 2000 (Invitrogen). STHdh
Q111
cells stably expressing VP16- PPARc2 were selected by treatment
with 2.5 mg/ml puromycin. Approximately 3 weeks later,
individual colonies were picked, amplified, and tested for the
expression and the activity of VP16- PPARc2. #12 and #41
clonal cells were selected and used for study.
Primary Cortical Neuronal Culture
Primary cortical neuronal culture from rat embryos was
prepared as described previously with modification [66]. In brief,
whole brains were removed from E17-18 rats. The cortices were
then dissected, treated with 0.05% trypsin at 37uC for 30 min, and
gently triturated with a fire polished glass Pasteur pipette.
Dissociated cells were plated onto glass-coverslips coated with
40 mg/ml poly-D-lysine (Millipore) with Minimum Essential
Media (MEM, Invitrogen) containing 25 mM Hepes and
GlutaMAX equivalent to 2 mM glutamine supplemented with
5% FBS in the incubator at 37uC containing 5% CO2. Five hours
after plating, medium was replaced with Neurobasal medium
(NBM, Invitrogen) supplemented with 0.4 mM glutamine and B27
(Invitrogen). Every 3 days, half of the medium was removed,
collected as conditioned NBM, and replenished with the complete
NBM.
Lactate Dehydrogenase (LDH) Release Assay
LDH release was measured using LDH release assay kit (Roche)
as an assessment of cell death. Cells were plated in 48 well plates
and were ,80–90% confluent after 24 h. Media were replaced
with different metabolic media in the absence or presence of
20 mM RSG for 24 h prior to TG or H2O2 treatment. Twelve
hours after TG or H2O2 treatment, LDH release was measured
following the manufacturer’s instructions.
Resazurin Assay
The cell viability was determined by monitoring conversion of
resazurin into a fluorescent product resorufin using CellTiter-Blue
Cell Viability Assay kit (Promega). Twenty four hours after plating
cells in 24 well plates, media were replaced with different
metabolic media. Next day cells were treated with TG or H2O2.
Resazurin solution was added to the media after 6 h according to
manufacturer’s instructions. Two hour after incubation, resorufin
fluorescence was measured using Synergy HT plate reader
(BioTek) with excitation at 540 nm and emission at 590 nm.
Results are presented as a percent of control cells.
RNA Isolation, Reverse Transcription, and Real-time PCR
Cells were plated followed by incubation in either glucose or
pyruvate media. After 24 h, total RNA was extracted using
TRIzol (Invitrogen) according to the manufacturer’s instruction.
Extracted total RNA was treated with RNase free- DNaseI
Amplification Grade (Invitrogen) to remove contaminating DNA.
Two micrograms of total RNA was reverse transcribed using
SuperScriptIII reverse transcriptase and random hexamers
(Invitrogen). The reaction mixture was diluted with 680 mlo f
DEPC-treated H2O. The PCR reaction was prepared in triplicate
containing 10 ml of diluted cDNA, 2.5 ml of 2.5 mM primer
mixture (forward and reverse), and 12.5 ml of SYBR GreenER
qPCR SuperMix (Invitrogen) in 96 well optical PCR reaction plate
(Bio-Rad). PCR reactions were performed in MyiQ real-time PCR
system (BioRad). Amplification conditions consisted of an initial
hot start at 95uC for 10 min followed by amplification of 45 cycles
(95uC for 15 s, 60uC for 20 s, and 72uC for 40 s). Melting curve
analysis was performed immediately after amplification. The
relative amount of mRNAs was calculated by using the DDCt (Ct,
threshold cycle) method. The Ct value of TATA binding protein
(TBP) was used for normalization. The sequences of primers are
shown in Table 1.
Western Blot Analysis
Cells were washed with ice-cold phosphate-buffered saline (PBS)
and lysed with modified RIPA buffer (50 mM Tris-HCl pH 7.4,
150 mM NaCl, 1% Triton X-100, 0.4% SDS, 0.2% sodium
deoxycholate, 5% glycerol, 1 mM EDTA, 20 mM NaF, 2 mM
Na3VO4) containing protease inhibitors (1 mM PMSF, 10 mg/ml
leupeptin, 10 mg/ml aprotinin, 10 mg/ml pepstatin). The lysates
were sonicated, cleared by centrifugation, and assayed to
determine protein concentration using BCA assay (Pierce
Biotechnology). Proteins (10–100 mg) were separated by SDS-
PAGE and transferred to nitrocellulose membrane. The mem-
brane was blocked with 5% skim milk in Tris-buffered saline
containing 0.05% Tween 20 (TBST), and incubated with the
specific antibodies in TBST containing 2% BSA or skim milk at
4uC overnight. Antibodies for PPARc (1:500), caspase 3 (1:1,000),
cleaved caspase 3 (1:1,000), caspase 9 (1:1,000), caspase 12
(1:1,000), cleaved PARP (1:1,000), and VDAC (1:2,000) were
acquired from Cell Signaling Technology, antibodies for hunting-
tin (1:1,000) and actin (1:50,000) were obtained from Chemicon,
the antibody for cytochrome C (1:2,000) was purchased from BD
Biosciences Pharmingen, the antibody for Bip/GRP78 (1:2,000)
was obtained from Stressgen, the antibody for cyclophilin D
(1:5,000) was purchased from Calbiochem, the antibody for a-
tubulin (1:2,000) was purchased from Santa Cruz Biotechnology,
and the antibody for Bcl-2 (1:1,000) was purchased from Sigma.
After washing three times, HRP-conjugated secondary antibody
(1:3000) in TBST containing 5% skim milk was applied and the
blot was visualized by chemiluminescence. The intensity of
immunoreactive bands was quantified by using Image J software.
Dual Luciferase Reporter Assays
Cells were plated in 24 well plate. The next day, a reporter
plasmid (36PPRE-Luc, PGC-1a promoter-Luc, mutPPRE-PGC-
1a promoter-Luc, mutCRE-PGC-1a promoter-Luc, or CRE-Luc)
and a normalizing plasmid phRL-TK (Promega) were transfected
using Lipofectamine 2000. The next day, cells were treated with
vehicle control or drug. After 16 h, cells were lysed with Passive
lysis buffer (Promega), and the reporter activity was measured
using the Dual-Luciferase Reporter Assay System (Promega). The
reporter activity from Firefly luciferase was normalized with the
Renilla luciferase activity.
Caspase Activity Assay
Cells were treated with 20 mM RSG for 24 h prior to TG
treatment in the glucose condition and then 12 mM TG was added
for 5 h. Cells were rinsed with cold PBS and harvested in 200 mlo f
NP40 lysis buffer (10 mM Tris, pH 7.5, 150 mM NaCl, 1 mM
EDTA, 1 mM EGTA, 0.5% NP40, 1 mM PMSF, 10 mg/ml of
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transferred into 96 well black wall plates, 200 ml of caspase assay
solution (20 mM Hepes, pH 7.5, 10% glycerol, 2 mM DTT)
containing 45 mM each caspase substrate [caspase-3 substrate (Ac-
DEVD-AMC), caspase-8 substrate (Ac-IETD-AMC), or caspase-9
substrate (Ac-LEHD-AMC)] was added to each well, and the
reaction mixture was incubated for 5 h at 37uC. Fluorescence was
measured using Synergy HT plate reader (BioTek) with excitation
at 360 nm and emission at 460 nm.
Measurement of Mitochondrial Membrane Potential
(DYm)
DYm was measured using 5,59,6,69-tetrachloro-1,19,3,3-tetra-
ethyl-benzimidazolyl-carbocyanine iodide (JC-1, Invitrogen) dye.
Higher DYm leads JC-1 to form aggregates that exhibit a red
emission, while lower DYm allows JC-1 to stay as a monomer that
yields a green emission. Cells were incubated with the different
metabolic media in the presence or absence of RSG with or
without GW9662. Twenty four hours later, cells were treated with
TG for the times indicated. After treatment, 5 mg/ml JC-1 was
added. Plates were wrapped with aluminum foil and returned to
the incubator. Thirty minutes later, cells were washed with PBS
and fluorescence was measured on Synergy HT plate reader with
the setup of green fluorescence (excitation at 485 nm and emission
at 528 nm) and red fluorescence (excitation at 540 nm and
emission at 590 nm). The ratio of red fluorescence to green
fluorescence was calculated as DYm and then JC-1 ratio from
each treatment was normalized by JC-1 ratio from the control of
each cell type.
Intracellular Superoxide/ROS Measurement
Superoxide/ROS generation was measured using DHE, a cell-
permeable reduced form of ethidium bromide which is not cell-
permeable. DHE itself exhibits a blue fluorescence in cytoplasm.
Oxidation especially by superoxide transforms DHE into oxidized
DHE products which exhibit a red fluorescence. The red
fluorescence of oxidized DHE products becomes much brighter
after DNA intercalation. Twenty four hours after plating striatal
cells, the media was replaced with the different metabolic media.
Imaging experiments for DHE were performed after 24 h.
Glucose medium was changed with G-HBSS consisting of HBSS
(20 Hepes, pH 7.4, 137 NaCl, 5 KCl, 0.5 KH2PO4, 0.5
Na2HPO4, 10 NaHCO3, 0.01 glycine; in mM), 2 mM CaCl2,
0.6 mM MgCl2, and 10 mM glucose, and pyruvate medium was
changed with Ox-HBSS consisting of HBSS, 2 mM CaCl2,
0.6 mM MgCl2, 5 mM galactose, 2 mM glutamine, and 1 mM
pyruvate. 5 mM DHE was included in G-HBSS or Ox-HBSS. TG
was added 10 min later. Plates were wrapped with aluminum foil
and replaced in the incubator. 30 min later, oxidized DHE was
imaged at 206 magnification on an Observer D1 microscope
(Zeiss) coupled with a digital CCD camera (ORCA-ER,
Hamamatsu Photonics). The red fluorescence from oxidized
DHE was detected by using a 545/40 excitation filter and a
630/75 emission filter with the same exposure time among each
experimental groups. DHE positive cells were counted using
Image J software. Primary cortical neurons were transfected with
0.8 mg of plasmids as indicated using Lipofectamine 2000 on DIV
7. Five hours after transfection, the media was replaced with half
conditioned NBM and half complete NBM. On DIV 13, neurons
were rinsed with G-HBSS and maintained in G-HBSS containing
2.5 mM DHE. Plates were wrapped with aluminum foil and
replaced in the incubator. One hour later, all GFP-positive
neurons were examined for DHE staining and photographed with
a4 0 6oil objective on the microscope system as described above.
DHE positive neurons were counted when the red fluorescence
occurred in the nucleus and its intensity was at least 50% higher
than that in cytoplasm.
Statistical Analysis
Data were expressed as mean 6 SE (standard error) and
analyzed using Student’s t test except where noted. Statistical
significance was considered when a P value was ,0.05.
Supporting Information
Figure S1 Glycolysis may contribute to the increased
sensitivity of STHdh
Q111 cells to stressors. Striatal cells
were treated with either 10 mg/ml oligomycin or 10 mM rotenone
to inhibit Oxphos in the glucose condition for 2 h prior to
Table 1. Primers used for real-time PCR.
GENES FORWARD PRIMER REVERSE PRIMER ACCESSION No.
PGC-1a GAAGTGGTGTAGCGACCAATC AATGAGGGCAATCCGTCTTCA NM_008904
PPARc GGAAGACCACTCGCATTCCTT TCGCACTTTGGTATTCTTGGAG NM_011146
SIRT1 GACGATGACAGAACGTCACAC TTCGAGGATCGGTGCCAATCA NM_019812
CytC CCAAATCTCCACGGTCTGTTC ATCAGGGTATCCTCTCCCCAG NM_007808
RXRa TGACATGCAGATGGACAAGACGGA TGCAGTACGCTTCTAGTGACGCAT NM_011305
UCP2 AGCCTACAAGACCATTGCACGAGA ATAGGTCACCAGCTCAGCACAGTT NM_011671
UCP4 TGCAAATGGAAGGGAAACGCAGAC AGCGCTGCTCTCTGAATATTGGGT AB106930
UCP5 AACCCTGTGGATGTGGTGAGAACT TGATGTTCCAGGGTCCAAGTCGAA AF155812
SOD1 GGTGTGGCCAATGTGTCCATTGAA TACTGCGCAATCCCAATCACTCCA NM_011434
SOD2 TTAAGGAGAAGCTGACAGCCGTGT TGTTGTTCCTTGCAATGGGTCCTG NM_013671
SERCA2 TGGGCAAAGTGTATCGACAGGACA GCAGGAACTTTGTCACCAACAGCA AJ223584
CypD AATGGGACAGGTGGCGAAAGTA CACATGTTTCCCGTCCAGATGA NM_026352
TBP ATGCCTTACGGCACAGGACTTACT AGTTGCTACTGCCTGCTGTTGTTG NM_013684
PGC-1a, peroxisome proliferator-activated receptor c (PPARc) coactivator-1a; SIRT1, sirtuin 1; CytC, cytochrome C; RXRa, retinoid X receptor a; UCP, uncoupling protein;
SOD, superoxide dismutase; SERCA2, sarco(endo)plasmic reticulum Ca
2+-ATPase 2; CypD, cyclophilin D; TBP, TATA binding protein.
doi:10.1371/journal.pone.0030406.t001
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treatment with H2O2 (A)o rT G( B) using the resazurin assay.
Oligomycin or rotenone treatment in the glucose condition led to
significantly reduced viability of STHdh
Q111 cells in response to
H2O2 or TG compared to STHdh
Q7 cells. n=5. Data shown are
mean 6 SE. * P,0.05, ** P,0.01.
(TIF)
Figure S2 STHdh
Q111 cells in the low glucose (5 mM)
condition still exhibit much greater cell death in
response to stressors. STHdh
Q7 and STHdh
Q111 cells were
maintained in the low glucose condition for 24 h prior to
treatment with stressors for 12 h. A,H 2O2 treatment resulted in
much greater cell death in STHdh
Q111 than STHdh
Q7 cells. B,
TG treatment also resulted in significant cell death in STHdh
Q111
cells while STHdh
Q7 cells were resistant to given treatment. n=2.
Data shown are mean 6 SD (standard deviation).
(TIF)
Figure S3 Knockdown of PPARc in STHdh
Q7 cells does
not increase sensitivity to stressors. A, STHdh
Q7 cells
stably expressing shRNA for PPARc were generated and show
significantly reduced PPRE activity compared to naı ¨ve STHdh
Q7
cells. n=3–4. B, Reduced PPARc activity in STHdh
Q7 cells does
not aggravate cell death in response to H2O2 or TG in the glucose
condition. n=3–6. Data shown are mean 6 SE.
(TIF)
Figure S4 STHdh
Q111 cells show a significant reduction
in the expression of Bcl-2 and cyclophilin D compared to
STHdh
Q7 cells. Cells were maintained for 24 h in the glucose
condition and harvested for either western blot or real-time PCR
as described in Experimental Procedures. A, Immunoblot results
show significantly reduced protein expression of Bcl-2 and
cyclophilin D (CypD) in STHdh
Q111 cells compared to STHdh
Q7
cells. n=4.B, The mRNA level of CypD is significantly reduced in
STHdh
Q111 cells. n=4.C, STHdh
Q7 and STHdh
Q111 cells were
incubated in the presence or absence of 20 mM RSG for 24 h.
RSG treatment does not change the protein expression of PPARc,
Bcl-2, CypD, or VADC. Data shown are mean 6 SE. * P,0.05,
*** P,0.001 vs. STHdh
Q7.
(TIF)
Figure S5 TG-induced cell death may not involve ER
stress or UPR response in the given condition. STHdh
Q7
and STHdh
Q111 cells were treated with and without 20 mM RSG
for 24 h in the glucose condition, and then 12 mM TG was treated
for 3 h or 5 h. Cells were harvested and prepared for western blot
analysis. TG treatment does not induce activation of caspase 12 or
increase expression of BiP/GRP78 in both cell types in the given
period of time. Interestingly, STHdh
Q111 cells exhibit higher level
of pro- and active caspase 12 compared to STHdh
Q7 cells. RSG
treatment does not have impact on either caspase 12 activation or
BiP/GRP78 induction.
(TIF)
Figure S6 The pyruvate condition results in a slight




maintained in the pyruvate condition for 24 h. Real-time PCR
was performed as described in materials and methods. n=4. The
relative mRNA levels of STHdh
Q111 cells to the corresponding
each gene of STHdh
Q7 cells were plotted. mRNA levels of PPARc
and UCP4 are decreased and mRNA level of UCP2 is highly
increased in STHdh
Q111 cells as shown in the glucose condition.
Similarly, mRNA levels of PGC-1a and SIRT1 are not different
between two cell types as shown in the glucose condition.
However, there is no difference in mRNA levels of CytC,
SOD1, SOD2, and SERCA2 between two cell types, which were
shown to be decreased in STHdh
Q111 cells. Data shown are mean
6 SE. * P,0.
(TIF)
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